Prulifloxacin Tablets

The drug targets bacterial DNA and inhibits the function of DNA topoisomerase II and IV, preventing bacterial DNA from forming supercoils and causing irreversible damage to chromosomes, which results in bacterial cells being unable to divide and reproduce, thus producing an antibacterial effect. This effect is generally highly selective for bacteria and safe for the human body.

Prulifloxacin. Chemical name: (plusmn;)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-1-piperazinyl]-4-oxo-4-hydrogen-[1,3]thiazine[3,2-a]quinoline-3-carboxylic acid.

This product should be slightly yellow or light yellow tablets.

It is used to treat the following infections caused by Staphylococcus aureus, gonococci, pneumococci, enterococci, Moraxella, Escherichia coli, Shigella, Salmonella (except typhoid and paratyphoid bacteria), citric acid bacteria, Klebsiella pneumoniae, Serratia, Proteus, Vibrio cholerae, Pseudomonas aeruginosa, and Streptococcus aureus that are sensitive to prulifloxacin: 1. Superficial skin infections (acute superficial folliculitis, infectious impotence), deep skin infections (cellulitis, erysipelas, furunculosis, furunculosis, carbuncle, suppurative perionychia), chronic pyoderma (infected sebaceous cysts, suppuration, etc.).

This product belongs to the quinolone antibiotics. It inhibits the activity of bacterial DNA topoisomerase II and IV, inhibits bacterial DNA synthesis, and completes the bactericidal effect. It is different from the traditional bactericidal mode and does not have the drug resistance phenomenon of other antibiotics. This drug has a broad antibacterial spectrum and has significant therapeutic effects on both Gram-negative and Gram-positive bacteria. It is particularly sensitive to Pseudomonas aeruginosa, and its antibacterial power exceeds that of other oxazolidinones and other currently marketed antibiotics.

Eosinopenia and elevated liver GPT were mild.

1. Patients who are allergic to this product or quinolone drugs are prohibited from using this product. 2. Pregnant women, lactating women and patients under 18 years old are prohibited from using this product.

Precautions for children: The safety of this product in infants with low birth weight, newborns, infants, toddlers and children has not been established, so it should not be used (see other precautions). Precautions for pregnancy and lactation: 1. This product is contraindicated for women who are pregnant or may be pregnant (the safety of administration during pregnancy has not been established). 2. It is best not to use this product for breastfeeding women. If you must take it, you should stop breastfeeding. (It is reported that in rat animal experiments, this product can enter breast milk). Precautions for the elderly: In pharmacokinetic studies in elderly patients, it was found that the half-life of the drug was prolonged, which may cause the drug to maintain a high concentration in the blood. Therefore, the drug should be administered with caution, with a reduced dose or at intervals.

This product is contraindicated for use with the following drugs: Drug name Clinical symptoms﹒ Measures and methods Mechanism﹒ Risk factors Fenbufen Flubifenazine Cefuroxime Flubifenazine May cause convulsions. If such symptoms are found, both types of drugs should be stopped and appropriate treatment measures should be taken. Enhance the inhibitory effect of this product on the binding of GABAA receptors and induce convulsions. Issues that should be noted when this product is used in combination with the following drugs: Drug name Clinical symptoms﹒ Measures and methods Mechanism﹒ Risk factors Aminophylline and aminophylline, etc. This product increases the concentration of theophylline in the blood and enhances its effect. If used in combination, appropriate measures should be taken, including reducing the dosage of theophylline. Because it produces a mild CYP1A inhibitory effect, it inhibits the metabolism of theophylline in the liver, increasing its concentration in the blood. Special attention should be paid to the elderly and patients with renal insufficiency.

seal.

0.1 g

18 months